395 related articles for article (PubMed ID: 7059981)
21. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.
Boyd VL; Robbins JD; Egan W; Ludeman SM
J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
23. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
24. The chemistry of the metabolites of cyclophosphamide.
Ludeman SM
Curr Pharm Des; 1999 Aug; 5(8):627-43. PubMed ID: 10469895
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
Gilbert DN; Starr P; Eubanks N
Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
[TBL] [Abstract][Full Text] [Related]
26. DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in postimplantation rat embryos.
Little SA; Mirkes PE
Cancer Res; 1987 Oct; 47(20):5421-6. PubMed ID: 3477317
[TBL] [Abstract][Full Text] [Related]
27. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: evidence for iminocyclophosphamide as an intermediate.
Borch RF; Getman KM
J Med Chem; 1984 Apr; 27(4):485-90. PubMed ID: 6708050
[TBL] [Abstract][Full Text] [Related]
28. Possible role of acrolein in 4-hydroperoxycyclophosphamide-induced cell damage in vitro.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1991; 13(1):11-4. PubMed ID: 1908032
[TBL] [Abstract][Full Text] [Related]
29. Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.
Seitz DE; Katterjohn CJ; Rinzel SM; Pearce HL
Cancer Res; 1989 Jul; 49(13):3525-8. PubMed ID: 2499418
[TBL] [Abstract][Full Text] [Related]
30. Effects of 4-hydroperoxycyclophosphamide (4-OOH-CP) and 4-hydroperoxydechlorocyclophosphamide (4-OOH-deCICP) on the cell cycle of post implantation rat embryos.
Little SA; Mirkes PE
Teratology; 1992 Feb; 45(2):163-73. PubMed ID: 1615426
[TBL] [Abstract][Full Text] [Related]
31. Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation.
Alarcon RA
Cancer Treat Rep; 1976 Apr; 60(4):327-35. PubMed ID: 1277208
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein.
Kawabata TT; White KL
Cancer Res; 1988 Jan; 48(1):41-5. PubMed ID: 3257162
[TBL] [Abstract][Full Text] [Related]
33. Interaction of cyclophosphamide with DNA in isolated rat liver cell nuclei.
Lindemann H
Anticancer Res; 1984; 4(1-2):53-8. PubMed ID: 6712177
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
35. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
36. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
Hohorst HJ; Draeger U; Peter G; Voelcker G
Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
[TBL] [Abstract][Full Text] [Related]
37. Two stable Fenton oxidation products of cyclophosphamide (NSC-26271) as precursors of 4-hydroxycyclophosphamide (NSC-196562) under physiologic conditions.
Benckhuysen C; van der Steen J; Spanjersberg EJ
Cancer Treat Rep; 1976 Apr; 60(4):369-72. PubMed ID: 945125
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Crook TR; Souhami RL; McLean AE
Cancer Res; 1986 Oct; 46(10):5029-34. PubMed ID: 3463409
[TBL] [Abstract][Full Text] [Related]
39. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
40. Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography.
Johansson M; Bielenstein M
J Chromatogr B Biomed Appl; 1994 Oct; 660(1):111-20. PubMed ID: 7858703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
